Stem Cells
Therapies
Stem Cells Therapies
The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).
FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.
Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.
Check the full list of patients who received stem cell therapy derived from FamiCord labs.
List last update: 06.2026
List of patients who received stem cells from FamiCord Group laboratories
| Lp. | Source | Source type | Diagnosis | Medical field | Year of application | Therapy | Country | Age of recipient |
|---|---|---|---|---|---|---|---|---|
| 2401 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 67 |
| 2402 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 66 |
| 2403 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 65 |
| 2404 | Apheresis | Autologous | Anaplastic Lymphoma Kinase Positive Anaplastic Large-Cell Lymphoma | Hematology | 2023 | Standard Therapy | Germany | 37 |
| 2405 | Apheresis | Allogeneic | Bare Lymphocyte Syndrome Type Ii | Hematology | 2023 | Standard Therapy | Poland | 3 |
| 2406 | Apheresis | Allogeneic | B-Cell Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 66 |
| 2407 | Apheresis | Allogeneic | B-Cell Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 49 |
| 2408 | Apheresis | Autologous | B-Cell Lymphoma | Hematology | 2023 | Standard Therapy | Germany | 66 |
| 2409 | Apheresis | Allogeneic | B-Cell Precursor Acute Lymphocytic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 53 |
| 2410 | Apheresis | Allogeneic | B-Cell Precursor Acute Lymphocytic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 27 |
| 2411 | Apheresis | Allogeneic | B-Cell Precursor Acute Lymphocytic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 51 |
| 2412 | Apheresis | Allogeneic | Beta Thalassemia Major | Hematology | 2023 | Standard Therapy | Poland | 4 |
| 2413 | Apheresis | Allogeneic | Blastic Plasmacytoid Dendritic Cell Neoplasm | Hematology | 2023 | Standard Therapy | Poland | 66 |
| 2414 | Apheresis | Allogeneic | Cell Neoplasm | Hematology | 2023 | Standard Therapy | Germany | 47 |
| 2415 | Apheresis | Allogeneic | Chronic Lymphocytic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 61 |
| 2416 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2023 | Standard Therapy | Poland | 43 |
| 2417 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2023 | Standard Therapy | Germany | 36 |
| 2418 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2023 | Standard Therapy | Poland | 62 |
| 2419 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2023 | Standard Therapy | Poland | 59 |
| 2420 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2023 | Standard Therapy | Poland | 37 |
| 2421 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2023 | Standard Therapy | Poland | 41 |
| 2422 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2023 | Standard Therapy | Poland | 54 |
| 2423 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2023 | Standard Therapy | Poland | 61 |
| 2424 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2023 | Standard Therapy | Poland | 54 |
| 2425 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2023 | Standard Therapy | Germany | 28 |
| 2426 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 62 |
| 2427 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 65 |
| 2428 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 64 |
| 2429 | Apheresis | Autologous | Composite Lymphoma | Hematology | 2023 | Standard Therapy | Germany | 71 |
| 2430 | Apheresis | Allogeneic | Congenital Pulmonary Lymphangiectasia | Hematology | 2023 | Standard Therapy | Poland | 50 |
| 2431 | Apheresis | Autologous | Diffuse Large B-Cell Lymphoma | Hematology | 2023 | Standard Therapy | Germany | 59 |
| 2432 | Apheresis | Allogeneic | Diffuse Large B-Cell Lymphoma | Hematology | 2023 | Standard Therapy | Poland | 50 |
| 2433 | Apheresis | Autologous | Diffuse Large B-Cell Lymphoma | Hematology | 2023 | Standard Therapy | Germany | 70 |
| 2434 | Apheresis | Allogeneic | Ewing Sarcoma | Hematology | 2023 | Standard Therapy | Poland | 62 |
| 2435 | Apheresis | Autologous | Follicular Lymphoma | Hematology | 2023 | Standard Therapy | Germany | 62 |
| 2436 | Apheresis | Allogeneic | Follicular Lymphoma | Hematology | 2023 | Standard Therapy | Poland | 53 |
| 2437 | Apheresis | Allogeneic | Hemophagocytic Lymphohistiocytosis (Hlh) | Hematology | 2023 | Standard Therapy | Poland | 4 |
| 2438 | Apheresis | Autologous | Hodgkin – Relapse | Hematology | 2023 | Standard Therapy | Germany | 43 |
| 2439 | Apheresis | Allogeneic | Huntington’s Disease (Hd) | Hematology | 2023 | Standard Therapy | Germany | 36 |
| 2440 | Apheresis | Allogeneic | Hypoplastic Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 27 |
| 2441 | Apheresis | Allogeneic | Immunodeficiency | Hematology | 2023 | Standard Therapy | Poland | 4 |
| 2442 | Apheresis | Allogeneic | Inherited Immune System Disorder | Hematology | 2023 | Standard Therapy | Poland | 16 |
| 2443 | Apheresis | Allogeneic | Langerhans Cell Sarcoma | Hematology | 2023 | Standard Therapy | Poland | 66 |
| 2444 | Apheresis | Autologous | Light-Chain Amyloidosis | Hematology | 2023 | Standard Therapy | Germany | 62 |
| 2445 | Apheresis | Allogeneic | Macrofocal Multiple Myeloma | Hematology | 2023 | Standard Therapy | Poland | 94 |
| 2446 | Apheresis | Autologous | Mantle Cell Lymphoma | Hematology | 2023 | Standard Therapy | Germany | 54 |
| 2447 | Apheresis | Autologous | Mantle Cell Lymphoma | Hematology | 2023 | Standard Therapy | Germany | 64 |
| 2448 | Apheresis | Allogeneic | Mast Cell Sarcoma, Systemic Mastocytosis Nr | Hematology | 2023 | Standard Therapy | Poland | 51 |
| 2449 | Apheresis | Allogeneic | Mixed Phenotype Acute Leukemia | Hematology | 2023 | Standard Therapy | Poland | 64 |
| 2450 | Apheresis | Autologous | Morbus Hodgkin | Hematology | 2023 | Standard Therapy | Germany | 43 |
| 2451 | Apheresis | Autologous | Morbus Hodgkin | Hematology | 2023 | Standard Therapy | Germany | 57 |
| 2452 | Apheresis | Allogeneic | Mucopolysaccharidosis /Myelodysplastic Syndrome Overlap | Hematology | 2023 | Standard Therapy | Poland | 71 |
| 2453 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 47 |
| 2454 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 53 |
| 2455 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 65 |
| 2456 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 60 |
| 2457 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 63 |
| 2458 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 63 |
| 2459 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 72 |
| 2460 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 61 |
| 2461 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 68 |
| 2462 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 54 |
| 2463 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 67 |
| 2464 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 69 |
| 2465 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 61 |
| 2466 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 63 |
| 2467 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 63 |
| 2468 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 61 |
| 2469 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 64 |
| 2470 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 69 |
| 2471 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 58 |
| 2472 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 56 |
| 2473 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 66 |
| 2474 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 63 |
| 2475 | Apheresis | Allogeneic | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Poland | 56 |
| 2476 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 53 |
| 2477 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 66 |
| 2478 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 59 |
| 2479 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 59 |
| 2480 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 64 |
| 2481 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 63 |
| 2482 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 68 |
| 2483 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 60 |
| 2484 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 42 |
| 2485 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 62 |
| 2486 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 50 |
| 2487 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 59 |
| 2488 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 56 |
| 2489 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 64 |
| 2490 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2023 | Standard Therapy | Germany | 59 |
| 2491 | Apheresis | Allogeneic | Mycosis Fungoides | Hematology | 2023 | Standard Therapy | Poland | 62 |
| 2492 | Apheresis | Allogeneic | Myelodysplastic Disorders | Hematology | 2023 | Standard Therapy | Poland | 57 |
| 2493 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 71 |
| 2494 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 64 |
| 2495 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 67 |
| 2496 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 56 |
| 2497 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 41 |
| 2498 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 70 |
| 2499 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 57 |
| 2500 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 70 |